NYSEAMERICAN:CVM Cel-Sci (CVM) Stock Price, News & Analysis $1.74 +0.03 (+1.75%) Closing price 10/15/2026 04:10 PM EasternExtended Trading$1.76 +0.02 (+1.21%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Cel-Sci Stock (NYSEAMERICAN:CVM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cel-Sci alerts:Sign Up Key Stats Today's Range$1.66▼$1.7850-Day Range$1.38▼$2.7452-Week Range$0.89▼$10.16Volume71,956 shsAverage Volume298,551 shsMarket Capitalization$30.42 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cel-Sci Corporation is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company’s lead product candidate is Multikine (leukocyte interleukin, injection), an investigational immunotherapy designed to activate and direct the immune system against cancer cells. Its development has primarily focused on the treatment of locally advanced primary head and neck cancer. Cel-Sci also develops therapies and vaccine candidates using its proprietary LEAPS technology platform. LEAPS, or L.E.A.P.S. (Ligand Epitope Antigen Presentation System), is designed to stimulate targeted immune responses and has been investigated for potential applications in cancer, viral infections, and other diseases. These candidates remain in development and are not broadly marketed as approved products. Founded in 1983, Cel-Sci is headquartered in Vienna, Virginia. The company conducts research and clinical development activities through collaborations and clinical programs in the United States and other countries. Cel-Sci is led by Geert R. Kersten, who serves as chief executive officer.AI Generated. May Contain Errors. Read More Cel-Sci Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreCVM MarketRank™: 0.380320546505 of 5 starsCel-Sci scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Cel-Sci. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Cel-Sci is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cel-Sci is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCel-Sci has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.76% of the float of Cel-Sci has been sold short.Short Interest Ratio / Days to CoverCel-Sci has a short interest ratio ("days to cover") of 4.14.Change versus previous monthShort interest in Cel-Sci has recently decreased by 4.33%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCel-Sci does not currently pay a dividend.Dividend GrowthCel-Sci does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Cel-Sci this week, compared to 0 articles on an average week.Search Interest5 people have searched for CVM on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows1 people have added Cel-Sci to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cel-Sci insiders have not sold or bought any company stock.Percentage Held by Insiders9.93% of the stock of Cel-Sci is held by insiders.Percentage Held by Institutions12.08% of the stock of Cel-Sci is held by institutions.Read more about Cel-Sci's insider trading history. Receive CVM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cel-Sci and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVM Stock News HeadlinesCel-Sci (NYSEAMERICAN:CVM) Stock Price Down 4.4% - Time to Sell?October 14 at 2:43 AM | americanbankingnews.comCEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and LaryngologySeptember 15, 2026 | finance.yahoo.comA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.October 16 at 1:00 AM | Investors Alley (Ad)CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and LaryngologySeptember 15, 2026 | businesswire.comCEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory ...August 4, 2026 | finance.yahoo.comCEL-SCI Corporate Event Calendar | AMEX:CVMJuly 16, 2026 | benzinga.comCEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck CancerJuly 13, 2026 | finance.yahoo.comCEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer CareJune 24, 2026 | businesswire.comSee More Headlines CVM Stock Analysis - Frequently Asked Questions How have CVM shares performed this year? Cel-Sci's stock was trading at $5.26 at the beginning of 2026. Since then, CVM shares have decreased by 66.9% and is now trading at $1.74. How were Cel-Sci's earnings last quarter? Cel-Sci Corporation (NYSEAMERICAN:CVM) released its earnings results on Friday, August, 14th. The company reported ($0.47) earnings per share for the quarter. When did Cel-Sci's stock split? Cel-Sci's stock reverse split on Thursday, June 15th 2017.The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Cel-Sci? Shares of CVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cel-Sci own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cel-Sci investors own include NVIDIA (NVDA), Canopy Growth (CGC), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Intel (INTC) and Tesla (TSLA). Company Calendar Last Earnings8/14/2026Today10/16/2026Fiscal Year End9/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, CVM's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:CVM CIK725363 Webcel-sci.com Phone703-506-9460Fax703-506-9471Employees44Year Founded1983Profitability EPS (Trailing Twelve Months)($9.77) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$25.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-250.83% Return on Assets-125.06% Debt Debt-to-Equity Ratio0.35 Current Ratio1.48 Quick Ratio1.42 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.32 per share Price / Book0.75Miscellaneous Outstanding Shares17,480,000Free Float15,742,000Market Cap$30.42 million OptionableNo Data Beta0.58 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NYSEAMERICAN:CVM) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredUndiscovered Sub-$1 Gold-Silver Royalty Stock Takes FlightA small-cap gold and silver royalty company is generating record revenue from producing mines, yet shares stil...Digest Publishing | SponsoredA simple options strategy that changed one trader's pathIan Cooper went from a financially stressed, struggling journalist to a trader who discovered a repeatable opt...TradeWins | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredWall Street Legend: “Global Market Freeze Coming”Dr. Martin D. Weiss, who predicted the Dot-Com collapse and the failures of Fannie Mae, Bear Stearns, and Lehm...Weiss Ratings | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | SponsoredElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cel-Sci Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Cel-Sci With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CVM Stock Alerts